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Abstract: 
The functions of anti-fouling, zwitterionic polycarboxybetaine (pCB) and anti-platelet nitric 
oxide (NO) release replicate key anticoagulant properties of the endothelium. The two 
approaches, only tested separately thus far, were paired on gas permeable 
polydimethylsiloxane (PDMS) membranes and evaluated for anti-coagulation.  Uncoated 
PDMS (control) and PDMS coated with pCB were screened for fibrinogen (Fg) fouling 
followed by platelet adsorption testing to evaluate the effects of coating and/or NO using 
bioreactors. Bare or coated PDMS membranes separated sheep plasma (108 platelets/ml) and 
gas flow chambers within the bioreactors. Either 100 or 0 ppm of NO/N2 flowed through the 
gas chamber for NO release at the plasma/biomaterial interface. Surface-adsorbed platelets 
were quantified using a lactate dehydrogenase assay after 8 hrs of plasma recirculation. Fg 
fouling and platelet adsorption on pCB-coated PDMS were 10.40 ± 3.0% of control (p<0.01) 
and 23.3 ± 7.4% (p<0.01) of control respectively. NO flux alone limited platelet adsorption to 
79.0 ± 5.0% (p<0.05) of control. Together, NO and pCB reduced platelet adsorption to 6.90 ± 
1.30% of the uncoated control (p<0.001). The data suggest that pCB coating and NO act in 
concert to reduce platelet fouling at significantly higher levels than either pCB coating or NO 
release alone. 
 
1. Introduction 
Blood contacting medical devices typically fail in the long-term due to clot formation. 
Significant advances have been made towards achieving materials capable of longer-term use, 
including 1) heparin coatings to reduce thrombin generation[1-3], 2) various coatings that resist 
adsorption of plasma proteins[4-6], and 3) nitric oxide gas to reduce platelet activation. [7-11] 
Each technology is inspired by a single mechanism of the rather multimodal approach used by 
the endothelium to control coagulation. Thus, each method provides a modest decrease in 
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surface clotting, but none has yielded the breakthrough needed to markedly slow device 
failure due to clot formation.  
 This paper describes a first step toward achieving an “artificial endothelium” to 
improve the functional lifetime blood-contacting devices such as artificial organs, vascular 
grafts, catheters, and cannulas. We couple anti-fouling zwitterionic functional groups, similar 
to those expressed by endothelial cells[12-13] with anti-platelet nitric oxide (NO), which is 
released by endothelial cells.[14-16]  
The rationale for using these two systems is graphically described in Figure 1.  
 
Figure 1. (A bio-inspired hypothesis that the conjugation of surface anti-platelet NO-
release/protein anti-fouling coatings on a surface can better limit blood activation; A surface 
modified for NO release alone, 1), will have to compete with contact activation of 
procoagulant proteins, and those modified with protein anti-fouling coatings alone, 2), will 
require unattainably high graft densities to remain non-fouling.  However, when NO release is 
combined with surface coatings, 3), the anti-platelet and low protein fouling conjugate effect 
can lead to lower blood activation.)  
 
Surfaces modified for NO release alone (1), will not be able to resist protein adsorption, have 
to compete with procoagulant proteins including the adsorption of fibrinogen, which is shown 
to increase on NO releasing surfaces. [17]  Surfaces modified with protein adsorption resistant 
coatings alone (2) will require very high, uniform graft densities to remain non-fouling. Any 
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imperfection in the coating can lead to fouling, and trigger coagulation. However, when NO 
release is combined with surface coatings, 3), procoagulant protein adsorption and subsequent 
platelet adhesion can be greatly limited by the coating while NO release inhibits platelets that 
approach regions of coating imperfection.  
Prior to this paper, we studied how surface NO flux and PMEA coatings 
synergistically affect platelet adsorption. [17] It was concluded in that paper that the PMEA 
significantly inhibits adsorption. However, more than 69.7 ± 6.8% reduction in platelet 
adsorption was achieved only when the PMEA was paired with high levels of NO flux. These 
findings led us to explore other anti-fouling coatings, which may exhibit a higher anti-fouling 
property. Published studies have demonstrated a lesser amount of protein fouling with pCB 
than PMEA coating.[17,18] We thus hypothesized that paring pCB with NO concentrations 
would lead to less platelet binding, and that this might allow for the use of lower NO surface 
flux.  
The anti-fouling property of polycarboxybetaine coatings has been well studied. On 
their own, pCB grafted surfaces have shown undetectable nonspecific protein adsorption 
(<0.3 ng cm-2) from single-protein solutions[19] or complex media[20,21] by surface plasmon 
resonance.  Nitric oxide releasing or generating surfaces are capable of reducing platelet 
adsorption by approximately 40%[22,11], and markedly reduce clot formation in artificial lungs. 
[23]  Unfortunately, in applications requiring large surface- area-to-volume-ratios (e.g. artificial 
lungs and kidneys) or small bore architecture (vascular grafts), NO secretion or zwitterionic 
grafting alone may not be adequate to counter coagulation and preserve device function, 
particularly when device use of weeks to months is required.  Nitric oxide release alone 
doesn’t limit protein adsorption, and thus, platelets can still bind and activate at the surface. 
Indeed, the adsorption of procoagulant fibrinogen has been shown to increase on nitric oxide-
rich surfaces. [24]  Anti-fouling coatings allowing even a small amount of protein adsorption 
will still allow some degree platelets binding that could promote thrombus formation.  
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  In the current study, PDMS membranes were either left uncoated or coated with pCB. 
Coated and uncoated surfaces were also made to release NO. NO flux has been achieved via 
materials approaches by incorporating a finite amount of NO donors into the substrate[22] or 
by catalytically generating NO via surface embedded micro and nano Cu particles. [23] 
However, NO delivery in gas exchangers like artificial lungs can be achieved by direct flow 
of NO gas.[25] To this effect, a bioreactor system was designed so that NO gas diffuses from 
the uncoated side of membranes to its pCB-coated surface. This system was used to test the 
synergistic effect of pCB coating and NO release on platelet adsorption from plasma. 
 
2. Results 
PDMS and pCB coated PDMS (PDMS-pCB) materials were analyzed using XPS. The survey 
scan is showed in Figure 2A and 2B.  CBMA coating on PDMS is about 4 nm (based on 
experiments on CBMA coatings on gold coated glass chips). The surface of PDMS coated 
with DOPA-pCB showed the presence of nitrogen (N 1s, about 2.4 atomic percent) and the 
silicon content reduced from 28.8 percent to 17.3 percent. See Table 1.   
 
Table 1. (Atomic percent of surface elements of uncoated PDMS and pCB coated PDMS.)  
 
 C 1s O 1s Si 2p N 1s 
PDMS 45.29 25.87 28.82  
PDMS-pCB 54.05 24.79 17.306 2.34 
 
High-resolution nitrogen spectra of uncoated PDMS and DOPA-pCB coated PDMS are 
shown in Figure 2C and 2D respectively. High-resolution N 1s spectra of PDMS coated with 
DOPA-pCB (Fig. 4D) exhibited two distinct peaks (N 1s, Pk01 ∼ 400.2 eV and Pk02 ∼ 402.7 
eV). The lower binding energy peak was assigned to N bound to C (C–N of polydopamine 
and pCB) while the higher binding energy peak was assigned to quaternary nitrogen (R3N+ of 
pCB).[26] This confirms the presence of polymeric coating on top of PDMS. Clealy PDMS did 
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not show any peaks in the region between 380-400 eV whereas the polymer coated surface 
showed significant presence of nitrogen (Figure 2C).  
 
Figure 2. (XPS survey scan of PDMS (A) and PDMS-pCB (B).  High resolution nitrogen 
spectra for PDMS (C) and PDMS-pCB (D).)  
 
PDMS coated with DOPA-pCB showed significant inhibition of fouling compared uncoated 
controls. The inhibition of fibrinogen adsorption on DOPA-pCB coated PDMS is shown in 
Figure 3. Fibrinogen fouling on DOPA-pCB coated PDMS was limited to 10.4 ± 3.0% of the 
uncoated PDMS surface.  The effect of the DOPA-pCB coating and NO flux on platelet 
binding are shown in Figure 4. As a result of decrease protein adsorption, Platelet adsorption 
on DOPA-pCB coated PDMS fell to 23.3 ± 7.4% of the uncoated control (p<0.01). NO flux 
alone also reduced platelet binding significantly (p<0.05), albeit to a lesser degree (79 ± 5% 
of control). The combination of NO release and polycarboxybetaine coating further decreased 
platelet adsorption to 6.9 ± 1.3% of that on untreated PDMS (p<0.001). This 93% reduction is 
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close to the sum of the reduction in platelet adhesion caused by the pCB coating (77%) and 
the NO (21%) alone.   
 
 
Figure 3. (Fibrinogen fouling on uncoated and pCB-coated PDMS substrates. Data is 
expressed as percentage of fouling on uncoated substrates.)  
 
 
 
 
Figure 4. (Platelet adsorption on NO-releasing, DOPApCB-coated PDMS. The synergistic 
effect of coating and NO release on platelet adsorption is compared the effects of coating 
alone, NO release alone, and plain PDMS surface. Data is expressed as percentage of fouling 
on uncoated substrates.)  
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The quantities of surface bound platelets on substrates tested are shown in Table 2. Using the 
mean value of platelets that adsorbed onto unmodified PDMS as the baseline, surface nitric 
oxide release from PDMS was able to prevent over 2 million platelets from adsorbing. On the 
other hand, PDMS coated with pCB prevented over 8 million platelets from adsorbing. On 
PDMS substrates modified to release nitric oxide and with pCB coating, over 10 million 
platelets from adsorbing. 
 
Table 2. (Platelet fouling on modified and unmodified polydimethylsiloxane substrates.) 
 
Substrate Absorbance Platelet Fouling [x106 cells*cm-2] 
PDMS 6.26 ± 2.70 10.76 ± 4.64 
PDMS-NO 4.96 ± 0.24   8.52 ± 0.41 
PDMS-pCB 1.46 ± 0.11   2.50 ± 0.18 
PDMS-pCB-NO 0.45 ± 0.01   0.76 ± 0.01  
 
2.1. Discussion 
Our findings confirm that the pairing of anti-platelet nitric oxide release and low fouling 
zwitterionic polycarboxybetaine polymer coating limits platelet fouling at a significantly 
higher level than achieved with either nitric oxide release or polycarboxybetaine alone.   
Based on the known anti-clotting mechanisms of NO and hydrophilic pCB coating, we 
hypothesized that the effects of NO and pCB coating should be additive. In theory, this 
approach acts much like the endothelium by attacking two separate means of activating 
coagulation. The concept of incorporating several anticoagulant functions of the endothelium 
on an artificial surface is not new, but the systems being combined here have never been 
tested in tandem. The results support the additive hypothesis. DOPA-pCB coating alone 
reduced platelet adsorption to 23.3 ± 7.4% of the uncoated control (p<0.01). The flux of 100 
ppm NO alone also reduced platelet binding significantly (p<0.05), albeit to a lesser degree 
(79 ± 5% of control). The combination of NO release and polycarboxybetaine coating further 
decreased platelet adsorption to 6.9 ± 1.3% of that on untreated PDMS (p<0.001). This 93% 
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reduction is close to the sum of the reduction in platelet adhesion caused by the pCB coating 
(77%) and the NO (21%) alone.   
Additive inhibition was expected because blood coagulation on artificial materials is 
initiated by clotting factors adsorbing and activating on the surface, but is accelerated by 
subsequent platelet activation via fibrinogen or thrombin. Here, pCB coating suppresses 
protein adsorption, reducing the amount of adsorbed fibrinogen, fibrin, and thrombin 
available to activate platelets. The NO blocks the propagation of any clot formation driven by 
platelets that were able to encounter these molecules by effecting conformational changes in 
platelets’  thrombin and fibrinogen surface receptors.  
These results compare favorably a similar study of this nature involving PMEA coated 
polypropylene and NO release.[17] While PMEA coating reduced platelet adsorption to 82.6 ± 
9.2% of uncoated control, pCB coating studied here reduced platelet adsorption to 23.3 ± 
7.4% of uncoated. When PMEA coating was combined with 100 ppm NO flow, platelet 
adsorption was reduced to 30.3 ± 6.8% of uncoated control. The combination of pCB coating 
with the same 100 ppm NO flow (NO flux = 1.03 ±0.41 x10-10 mol/min/cm2) reduced platelet 
adsorption to 6.90 ± 1.30% of uncoated control. With PMEA coating, it is estimated that it 
would require 200 ppm of NO flow and an NO flux of 2.40 ± 1.63 x 10 −10 mol/min/cm2 to 
achieve similar results.[17] Thus, pCB allows for lower NO levels to be used without 
sacrificing biocompatibility, and lowers the risk of elevated methemoglobin concentrations 
(metHb). The NO flux (1.03 ±0.41 x10-10 mol/min/cm2) generated in this study is within the 
range of published endothelial NO flux levels. This level of NO flux is an order of magnitude 
lower than most papers showing effective inhibition of coagulation at an artificial surface. [2,8-
11,17] 
Much like the effectiveness of NO depends on its flux, the effectiveness of the pCB 
coating depends on the its coverage of the base polymer (PDMS) and its stability. As the 
coating of hydrophobic materials (e.g. PDMS) with hydrophilic polymers (e.g. pCB) is a 
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challenge, further optimization methods are being investigated to develop best coating 
processes. [27] They include i) dopamine assisted catechol chain end carboxybetaine 
methacrylate coating and ii) adding organic, water-miscible solvents into the coating solvent 
(TRIS buffer). The first method should increase hydrophobic interactions between the 
hydrophobic substrate and the dopamine assisted catechol chain end of carboxybetaine 
methacrylate. It has been reported that dopamine self-polymerize to polydopamine[28 -31] under 
basic conditions and this binds to the surface through adhesive interaction between 
catechol/surface and cohesive interaction among catechol. [32 -38] The exact mechanism for the 
formation of polydopamine is still not clear, although it was accepted that under basic 
conditions the catechol oxidizes to quinone, which then reacts with amine groups of dopamine. 
[29-31]  While mixing a polymer with DOPA chain end (DOPA-pCB) along with dopamine, the 
DOPA end of the polymer chain would react to dopamine of polydopamine and thus becomes 
attached to polydopamine. This technique has been used to coat DOPA-pCB polymer on to a 
variety of different surfaces, including this study. Further improvements in coating efficiency 
could be achieved through the addition of water miscible solvents such as methanol and 
tetrahydrofuran. This should increase the wettability of hydrophobic surfaces to aid coating 
uniformity. These and other optimization methods are aimed at reducing fibrinogen fouling to 
within ~5% of fouling on uncoated controls. 
Despite these positive results, several questions must be answered to determine if this 
approach is beneficial in clinical applications. First, the stability of pCB coatings under long-
term in vivo blood flow is unknown.[18] The coating must remain attached and functional to 
maintain its anti-coagulant properties. Previous results demonstrate promise, however. Lightly 
cross-linked poly(carboxybetaine methacrylate) hydrogels were able to maintain normal 
glucose sensor function for 42 days in whole blood. [39]  Second, optimal and safe levels of 
NO are unknown. Larger NO concentrations will lead to more effective inhibition of platelets. 
A previous study by our group demonstrated complete elimination of platelet binding on bare 
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polypropylene using 500 ppm of NO with a flux of 11.17  x 10−10 mol min-1cm-2. However, 
larger NO flux could lead to elevated levels of metHb and impaired oxygen delivery in 
patients. The ideal safe level will depend on the surface area of the device. Smaller surface 
area devices, such as cannulae and catheters are unlikely to cause increase metHb at any 
reasonable NO flux, while larger surface area devices like artificial lungs have the potential to 
raise metHb levels at larger fluxes. For comparison, 10-80 ppm of inhaled NO has been used 
safely for days in patients, leading to significant increases in metHb of up to 5-7% but only in 
the 80 ppm groups. [40, 41]  However, the adult lung has a huge surface area of 85 m2 or greater 
and should transfer markedly more NO than an adult artificial lung with a surface area of 1-2 
m2. This suggests that 100 ppm NO in an artificial lung should also be safe, but long-term in 
vivo testing must be done to verify. 
The effect of our test surfaces on other cell types must also be worked out. Based on 
the physical properties of samples tested, there are three possible types of interactions that can 
take place between the sample surface and blood cells. Since the surfaces released NO gas, 
and presented pCB polymer brushes to flowing media, blood cells including platelets, red 
blood cells, and white cells would interact with pCB, NO, and PDMS to different degrees. NO 
can also bind to the heme centers of red blood cells, generating methemoglobin and 
temporarily reducing the oxygen-carrying capacity of blood. For this reason, methemoglobin 
levels are monitored when delivering NO to blood. Endogenous NO has been shown to have 
an effect on white cells. In our published extra-corporeal recirculation study, systemic white 
cell counts were significantly lower in the NO generating artificial lungs group than in control 
lungs, which did not generate NO. [9] Other studies also accounted that increased endogenous 
NO levels is associated with decreased neutrophil sequestration. [44]  The nature of interaction 
between blood elements and pCB is different than with NO. Since surfaces coated with pCB 
groups are highly resistant to nonspecific adsorption due to electrostatically induced hydration, 
[38] they may reduce inflammatory reactions from occurring as a result of higher levels of 
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activated complement and intrinsic coagulation cascade activation. The interaction between 
procoagulant PDMS and blood elements lead to protein adsorption, followed by platelet, red 
blood cell, white cell adhesion, and solid clot formation. While pCB is highly biocompatible 
with no known toxic effects, NO flux released from test samples is comparable to levels 
released by endothelial cells and thus will pose reversible effects on blood cells.   
In addition the evaluation of resistance to clot formation by medical devices would 
greatly benefit from a standardized approach. There is, unfortunately, no established standard 
criterion for evaluating thrombogenicity in medical devices. Thus, strategies to evaluate and 
combat clot formation vary widely. Data on clot formation is based on a mixed bag of in vitro 
and in vivo test settings. The gold standard is long-term in vivo testing; however, there is no 
guarantee that these results will translate accurately to clinical use. Clot formation and device 
failure is based on a wide range of variables, many of which are never assayed, and remains 
highly variable from patient to patient and animal to animal. A standard translatable approach 
is certainly needed, but it is not yet known what is ideal. 
The following limitations should also be considered in the interpretation of our results. 
First, both NO and surface–generated procoagulant molecules accumulate over time in our 
system because it is a closed in-vitro circuit. Such accumulation would not occur in-vivo due 
to NO sinks in the patient and clearance of procoagulant molecules. Second, NO flux will also 
be different in blood due to the presence of red blood cells. The red blood cells scavenge NO 
after it travels through the plasma exclusionary layer near the biomaterial surface. This sink 
will limit NO’s effect in the bulk flow but also shrink the diffusional boundary layer and 
increase NO flux. Third, the effect of NO will vary slightly if NO is catalytically generated 
from donors in blood [7-9, 23,25] or supplied via the sweep gas in artificial lungs. In this later 
case, NO gas will react with O2 prior to delivery to the blood-contacting surface, reducing 
delivery of NO and increase delivery of nitrite and nitrate.   
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3. Conclusion 
 
Both DOPA-pCB and NO flux significantly reduced platelet adhesion to biomaterial surfaces, 
with DOPA-pCB having a greater effect than NO.  Together, they reduced platelet adhesion 
synergistically with a total platelet reduction that was similar to the sum of the reductions 
from each separately. The reduction in platelet adhesion with pCB was superior to that 
previously measured using a PMEA coating. Furthermore, the excellent resistance to 
fibrinogen fouling achieved using the pCB coating allowed for nearly complete (94%) 
reduction in platelet adhesion with even low levels of NO flux (1.03 ±0.41 x10-10 mol min-1 
cm-2). Thus, the pairing of low-level, anti-platelet NO release with DOPA-pCB has excellent 
promise toward surfaces with marked reductions in long-term coagulation. 
 
 
4. Experimental Section  
 
Surface attachment of zwitterionic polycarboxybetain polymer by “graft-to” method: 
Using already reported protocol [26, 27, 29, 30,43], Carboxybetaine methacrylate (CBMA) 
monomers were polymerized into DOPA-terminated pCB (DOPA-pCB) polymer via atomic 
transfer radical polymerization (ATRP). Dopamine is a highly adhesive molecule that 
essentially adheres and self-polymerizes at pH=8.5 on many surfaces including PDMS.  
DOPA-pCB synthesis is shown in Figure 5A.  First, dopamine (100mg) was conjugated to 2-
bromo isobutyl bromide (Br-i-Bu-Br) initiator (1.5ml) by first adding dopamine into a 50 ml 
glass tube and covered with a rubber stopper. Then the stopper was wrapped with parafilm 
followed by purging the glass tube with nitrogen. While the glass tube was under vacuum, 20 
ml of nitrogen-purged toluene (15 minutes) and 2 ml of pyridine was added. The tube was 
then placed on ice and the initiator was added drop-by-drop over 30 minutes. The exothermic 
solution was left stirring overnight under nitrogen. The resulting DOPA-Br conjugate was 
vacuum dried for 2 hours after discarding its solvent. The conjugate was then lyophilized for 
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24hrs. In a fresh 50 ml glass tube, 55mg/ml CBMA monomer was added to 20 ml nitrogen-
purged water (1hr) and covered with rubber stopper. The solution was then subjected to 5 
cycles of 20 minutes of purging with nitrogen and 30 seconds vacuum and then left to stir for 
15 minutes. 1 ml of separately prepared complex copper solution was added to previous 
solution and left stirring overnight under nitrogen. The complex copper solution was prepared 
by adding 33 mg CuBr and 4 mg CuBr2 in a 10 ml glass tube, followed by adding 2ml of 
purged water and 100 uL of 1,1,4,7,10,10-Hexamethyltriethylenetetramine (HMTETA) and 
stirring for 10 minutes. The resulting polymer was deprotected in 10ml tetrahydrofuran (THF) 
with 5mg tetra-n-butylammonium fluoride (TBAF) to remove silanes on the DOPA of 
DOPA-pCB. The DOPA-pCB conjugate was vacuum dried for 2 hours after discarding its 
solvent and then lyophilized overnight. 
DOPA-pCB polymer was then grafted onto PDMS substrates using 1:6 free DOPA to DOPA-
pCB polymer dissolved in tris(hydroxymethyl)aminomethane (TRIS) buffer (pH=8.5). The 
grafting process is shown in Figure 5B. Substrates were first cleaned in methanol for 5 
minutes and rinsed with water. They were then dried under nitrogen before immersing them in 
the above solution and initiating agitation for coating.  
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Figure 5. ((A) Dopamine-polyCarboxybetaine (DOPA-pCB) was synthesized via solution 
atomic transfer radical polymerization using an already reported protocol26.  The reaction 
sequence starts with A) the reaction of dopamine (DOPA) linker  with 2-bromo isobutyl 
bromide (Br-i-Bu-Br) initiator to form DOPA-Br, then 2) the reaction of DOPA-Br with 
polyCarboxybetaine methacrylate (CBMA) for form DOPA-pCB. B) Substrate’s surface 
modification with DOPA-pCB polymer via pseudo one step “graft-to” coating approach. 1:6 
free DOPA to DOPA-pCB were blended into a 2.5mg/ml in 
tris(hydroxymethyl)aminomethane (TRIS) buffer (pH=8.5) and was used to bathe substrates 
for 6hrs.))  
 
DOPA served as the linker molecule between the substrate and DOPA-pCB polymer. As 
described in our published work [27], the theory is that free catechol, DOPA either polymerizes 
into rafts in TRIS at pH=8.5 and deposits onto PDMS or forms aggregates after deposition. 
The surface DOPA network then provides anchoring sites for the DOPA chain end of DOPA-
pCB polymer brush via DOPA-DOPA polymerization. All solvents, chemicals, and 
complexes were purchased from Sigma Aldrich, St Louis MO.   
 After attachment, substrates were gently rinsed with deionized water to remove 
unbound or loosely attached DOPA-pCB and then stored in phosphate buffered saline, PBS 
(pH 7.34) under 4oC conditions for further testing. The samples stored in phosphate buffered 
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saline were then shipped on dry ice from University of Washington to the University of 
Michigan for biocompatibility testing.  The modified surfaces were examined for pCB 
attachment using X-ray photoelectric spectroscopy. Detection of nitrogen indicated 
attachment of pCB. Previous screening for optimal coating conditions using fouling data 
showed that 1 part DOPA to 6 parts DOPA-pCB suspended in TRIS buffer, resulting in a 
2.5mg/ml blend concentration, yields the lowest specific protein adsorption under specific 
coating conditions.[26]  These conditions include 1) using a 1.5 ml of blend for every 4 cm2 of 
grafting surface area and 2) wet-grafting for 6 hr.  
 
Protein adsorption: 
A standard ELISA method was used to quantify protein adsorption binding to the surfaces 
using horseradish peroxidase-conjugated anti-IgG adsorption. [13]  The samples were first 
incubated for 1.5 h in human plasma fibrinogen dissolved in PBS (3.0 mg/ml, pH 7.34) in 24-
well plate. They were then rinsed 5x to wash out unbound fibrinogen and transferred into a 
new 24-well plate. 200 microliters of 1 µg/mL HRP-conjugated goat anti-human IgG antibody 
was added to each sample and incubated for 1 h. This was followed by five rinses with PBS 
buffer. All samples (uncoated and the DOPA-PCB-100 coated) were moved to new wells. 
Next, 1 mL of 1 mg/mL o-phenylenediamine (OPD) in 0.1 M citrate phosphate buffer (pH 
5.5) containing 0.03% hydrogen peroxide was added. In the presence of hydrogen peroxide, 
peroxidase enzyme conjugated to anti-IgG catalyzes the oxidation of nearly colorless OPD to 
a soluble yellow-orange product. Peroxidase enzyme activity was stopped by adding 1 mL of 
1 N HCl after 15 min. Finally, the absorbance of the yellow-orange color solution (intensity is 
proportional to the amount of protein adsorption) was then measured at 492 nm.  
 
Surface analysis of modified substrates: 
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The surface of modified PDMS was evaluated using X-ray photoelectron spectroscopy. The 
surface analysis experiments were done at Surface Analysis Recharge Center, NESAC/BIO 
supported by NIBIB grant EB-002027. All XPS spectra were taken on a Surface Science 
Instruments S-probe spectrometer. This instrument has a monochromatized Al Kα X-ray and 
a low energy electron flood gun for charge neutralization of non-conducting samples.   The 
samples were fastened to the sample holder with double sided tape and run as insulators.  X-
ray spot size for these acquisitions was approximately 800 µm. Pressure in the analytical 
chamber during spectral acquisition was less than 5 x 10-9 Torr.  Pass energy for survey 
spectra (to calculate composition) was 150 eV and pass energy for high resolution scans was 
50eV.  The take-off angle (the angle between the sample normal and the input axis of the 
energy analyzer) was 0º (0º take-off angle ~ 100 Å sampling depth).  The binding energy 
scales of the high-resolution spectra were calibrated by assigning the most intense C1s high-
resolution peak a binding energy of 285.0 eV. Two spots were analyzed on each sample. 
 
Bioreactor flow cell and test circuit: 
Custom-built, polycarbonate bioreactor flow cells were fabricated to facilitate simultaneous 
flows of complex media and NO.  Test surfaces were inserted in the flow cell as shown in 
Figure 6, where blood plasma flows over the modified surface and NO travels from the gas 
phase, through the modified and unmodified surface, and then into the plasma. The bioreactor 
flow cell allows a total membrane surface area of 7.7 cm2 to be tested. Each flow cell was 
connected to a circuit consisting of 3/16’’ inner diameter Tygon tubes (Fisher Scientific, 
Pittsburg, PA) to form a closed serial circuit. After the circuits had been filled with plasma 
and all gas pockets eliminated, they were inserted into roller pumps (Stockert multiflow, 
Baxter Century Baxter Healthcare Cooperation Irvine, CA) to recirculate the plasma.  
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Figure 6. (Bioreactor flow cell; exploded view of flow cell showing platelet rich plasma 
(PRP) flow chamber, test membrane, and sweep gas flow chamber (A) and assembled 
bioreactor showing PRP and NO gas counter-current flow (B).)   
 
Quantifying nitric oxide flux from membranes: 
The methods for measuring NO flux from gas permeable membranes have been previously 
described. [17] In brief, the relationship between sweep gas NO concentration and the 
membrane NO flux was determined using PBS recirculation within the bioreactor circuit. This 
is a conservative estimate of NO flux during our plasma experiments, below. In plasma, some 
NO would bind to proteins, leading to a slightly higher effective diffusivity. A total of 55 mL 
of PBS (25 ml to fill bioreactor + 30 ml reservoir) was recirculated on one side of the 
membrane at 60 mL/min, while N2 with 100 ppm and 500ppm of NO flowed over the 
opposite surface. Two NO concentrations were used here only to ascertain that membrane NO 
flux changes with NO concentration. PBS samples were taken before initiating flow and at 
3min, 5min, 10min, 20min and 30min of recirculation. PBS NO concentrations were 
immediately measured with a Sievers Nitric Oxide Analyzer 280i (GE Instruments, Boulder, 
CO) using standard wet-phase measurement methods. The NO flux at each sampling time, JNO 
(mol/min/cm2), was first calculated as ([NO]c - [NO]p)/((tc – tp)*A), where [NO]c  and [NO]p 
are NO concentrations at the current and previous time points, tc - tp is the sampling time 
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interval, and A is the membrane surface area. JNO at each time point was then used to calculate 
the NO mass transfer coefficient, K (cm/min), for each time point. K was calculated as K = 
JNO/([NO]max - [NO]measured), where [NO]max (mol/ml) is the maximum achievable [NO] in PBS 
at the temperature and pressure from the NO gas concentration.  Maximum fluid NO 
concentration, [NO]max, was calculated as solubility(NO) x pNO, where solubility(NO) is the 
Henry’s constant for solubility of NO in water at standard temperature and pressure (1.94 x 
10−3 mol L−1 atm−1)[17] and pNO is the partial pressure of NO in N2 gas obtained as 
NO(ppm)x1atm. 
 
Platelet Adhesion Studies: 
The methods used here have been previously published. [17] In brief, all platelet adhesion 
studies utilized freshly drawn sheep plasma. Animal handling and surgical procedures were 
approved by the University Committee on the Use and Care of Animals in accordance with 
University of Michigan and federal regulations. Sheep whole blood was gravity drawn into a 
blood transfer blood bag (1:10 acid citrate dextrose 4% (ACD) anticoagulant, Sigma Aldrich, 
St Louis, MO). Whole blood from the bag was then carefully transferred to 50 mL centrifuge 
tubes and centrifuged at 730 rpm for 20 min to generate PRP. Platelet rich plasma was then 
recovered, and the remaining blood was centrifuged at 2750 rpm for 15 min to obtain platelet 
poor plasma (PPP). A Beckman-Coulter particle counter (Z1 Coulter Particle Counter, 
Indianapolis IN) was then used to determine platelet counts of the PRP and PPP. The PRP and 
PPP were then mixed to obtain 1x108 cells/mL.  
 Twenty-five mL of this mixture was injected into each bioreactor circuit. . Prior to 
injection, each bioreactor was fitted with a PDMS membrane that was uncoated or coated 
with pCB. The PRP flow rate was set to 60 ml/min as measured by a transonic flow probes 
(Transonic Systems, Ithaca, NY). Lastly, the sweep gas was nitrogen with 100 ppm of NO set 
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at a flow rate twice the PRP flow rate. Based on modeling (see Results), this should lead to an 
approximately NO flux of 1.03 ±0.41 x10-10 mol min-1cm-2. 
 To reduce biases created by run-to-run variability, four circuits were always run 
simultaneously such that four experimental conditions could be run with the same batch of 
plasma. In each run, four conditions were randomly chosen from all possible combinations of 
surfaces including PDMS, pCB-coated PDMS, PDMS with 100 ppm NO flow, and pCB-
coated PDMS with 100 ppm NO flow. A total of N=5 runs were conducted for uncoated 
PDMS, PDMS coated with pCB, and PDMS with 100ppm NO and N = 3 for pCB-coated 
PDMS with 100 ppm NO flow. The membranes were then carefully removed from the 
bioreactors and rinsed 3x in PBS using a 3mL pipette to wash away non-adhered blood 
plasma elements. The membrane was then sectioned lengthwise into two halves. One half was 
assayed for lactate dehydrogenase (LDH), and the other half was fixed for SEM analysis. 
Experimental runs with four circuits were repeated until five experiments were performed for 
each substrate coating and NO concentration combination. 
 A LDH assay kit (Cayman Chemicals Ann Arbor, 10008882) was used to quantify 
platelets adhered on the surface of each membrane. Each membrane section was incubated at 
37ºC in two mL of lysing reagent (1% Triton-X100, 0.75% Bovine Albumin Serum in 
phosphate buffered saline) for 1hr, with occasional agitation. The suspension was then 
assayed for LDH according to the kit manufacturer's protocol.  To convert LDH concentration 
to the number of adhered cells, a calibration curve was first constructed. PRP (7x108 
platelets/mL) was serially diluted with PPP to achieve platelet concentrations of 4.7x108, 
2.4x108, 1.2x108, 6.0x107, 3.0x107, 1.5x107, and 7.5x106 cell/ml and were assayed for LDH. 
A linear curve fit was then used to determine the relationship between absorbance from LDH 
and number of cells. This curve was found to be LDHabsorbance = 0.119 x platelets (x106 
cells/mL) + 0.010, (R2 = 0.99). 
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 To generate SEM images, the other half of the membrane was fixed with 2% 
gluteraldehyde (Sigma Aldrich, ST Louis MO) overnight and then dehydrated in a series of 
ethanol solutions and completely dried. The mid-section of the membrane was cut, sputter-
coated with gold, and imaged by a Hitachi S-3200N scanning electron microscope (15 kV). 
 
Data and Statistical Analysis: 
For fibrinogen adsorption, the absorbance of blank PBS solution at 492 nm was subtracted 
from the absorbance obtained from yellow-orange solutions in which samples were incubated 
to generate the absorbance due to fibrinogen. For quantitative comparison, all absorbance 
were presented as a percentage of the average fouling on uncoated PDMS samples (controls, 
N=5).  Similarly the raw LDH data were adjusted to remove background absorbance 
occurring on surfaces with zero platelet adherence. To do so, a control study was run using 
PBS only in the circuit, and these membranes were assayed for LDH in the described manner 
(N=4). The average background LDH data was then subtracted from the LDH concentrations 
measured in all studies. Adjusted LDH data from treated samples were then expressed as a 
percentage of the adjusted LDH concentration obtained from uncoated, control membranes 
after a normal PRP exposure study. Lastly, the calibration curve between LDH and platelet 
count was used to determine the number of adhered platelets, which was then divided by the 
surface area of test sample to give platelets/cm2. One-way analysis of variance (ANOVA) 
with a Tukey’s post hoc analysis was used to compare normalized intra-group fouling and 
LDH data using the SPSS (Chicago, IL). Statistical significance was set to p<0.05. Numerical 
values are presented as mean +/- standard deviation.   
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